£10.5bn in turnover. Scotland hosts the UK’s National Manufacturing Institute for Scotland, the world’s first national medicines manufacturing centre, and a unified NHS clinical trial infrastructure that no fragmented health system can replicate.
Sector turnover — 2025
Sector target by 2035
Organisations in sector
People employed
Scotland’s life sciences competitive advantage rests on an asset that no comparable economy can replicate: a unified national health service covering five million people with a single electronic health record system. For clinical trial operators, this creates a recruitment, data, and follow-up infrastructure that fragmented health systems — including the United States, Germany, and most of Western Europe — simply cannot match. Scotland can recruit, monitor, and follow trial participants at a scale and speed that makes it consistently attractive to multinational pharmaceutical companies.
The sector has grown to £10.5bn in turnover across over 900 organisations employing 40,000 people. The cluster is anchored by global majors — GSK has a significant manufacturing presence in Montrose, AstraZeneca operates from multiple Scottish sites, and Pfizer, Novartis, and Thermo Fisher all have established Scottish operations. The supply chain that supports these anchors has grown into a self-sustaining ecosystem.
The National Manufacturing Institute for Scotland, opened in 2021, includes the Medicines Manufacturing Innovation Centre — a world-first facility explicitly designed to solve the manufacturing scale-up challenge that kills most promising drug candidates. For pharmaceutical companies, NMIS represents de-risked manufacturing development unavailable anywhere else in the world at this scale and with this level of public-private infrastructure.
Scotland’s academic base provides the innovation pipeline. The University of Edinburgh, University of Glasgow, and University of Strathclyde all have internationally ranked medical schools and life sciences research departments. The Roslin Institute — home of Dolly the sheep, the world’s first cloned mammal — remains one of the world’s leading animal bioscience research centres. The interface between academic research and commercial application in Scotland’s life sciences is structurally more fluid than in most comparable regions.
The Scottish Government’s Life Sciences Strategy 2025 targets £25bn in sector turnover by 2035 — an ambition underpinned by £1bn in public investment committed across the strategy period. Inward investment into the sector reached record levels in 2024, with multiple US and European pharmaceutical and medtech companies establishing or expanding Scottish operations.
Sector turnover
£10.5bn — 2025
2035 target
£25bn — Scottish Govt
Organisations
900+ in sector
Employment
40,000 people
NHS clinical trials
Unified single-record system
NMIS
World-first facility — Renfrewshire
Roslin Institute
Home of Dolly the sheep
Scottish Government Life Sciences target: £25bn turnover by 2035. Capital allocation decisions happening now.
Scotland.com — operational since 1995. Five partnership pathways available.